Esperion(US:ESPR)2025-05-06 11:18Financial Performance - Total revenue reached $65 million, reflecting a 63% increase adjusting for a one-time settlement agreement milestone received in Q1 2024[9] - U S net product sales grew by 41% to $34 9 million[10] - Collaboration revenue was $30 1 million[34] Prescription Trends - Q1 2025 script growth increased by 2% compared to Q4 2024[15, 16] - Early Q2 2025 prescription volume is tracking approximately 8% higher than Q1 2025[16] Market Access and Clinical Validation - The company tripled the U S field reimbursement team to 15 specialists[12] - Over 30 major healthcare plans removed prior authorizations and expanded formulary coverage for NEXLETOL and NEXLIZET[12] Global Expansion - Products are approved in 40 countries globally[21] - Approximately 472,500 patients have been reached internationally through February 2025[24] Pipeline Development - The company is developing a triple combination product with an estimated LDL-C reduction of approximately 60%-70%[19] - A program targeting Primary Sclerosing Cholangitis (PSC) is in development, with an IND planned for 2026, addressing a market opportunity estimated at over $1 billion annually[27, 30]